You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)與英矽智能達成多靶點藥物研發戰略合作
阿思達克 01-11 17:40
復星醫藥(02196.HK)(600196.SH)宣布與端到端人工智能驅動的藥物研發公司英矽智能達成戰略合作協議,將在全球範圍內共同推進多個靶點的AI藥物研發。 合作包括針對四個指定靶點的以人工智能驅動的藥物研發合作,以及雙方對於英矽智能QPCTL項目的共同開發合作,英矽智能將獲得1,300萬美元的首付款及里程碑式付款,並分享QPCTL項目的商業化利潤。 此外,復星醫藥將向英矽智能提供股權投資,復星醫藥將獲得英矽智能人工智能平台PandaOmics和Chemistry42的使用權,以推進公司內部人工智能驅動的藥物發現和開發工作。 是次合作旨在將英矽智能端到端人工智能驅動的藥物發現平台,與復星醫藥強大的臨床開發和商業推廣能力相結合,發現和開發創新藥物和療法的組合。 根據合作協議,英矽智能將負責為QPCTL項目提名臨床前候選藥物,並將該候選藥物推進到臨床前階段,之後復星醫藥將對其展開臨床階段研究,共同推進該項目在全球範圍內的開發。同時,復星醫藥的研發團隊將提名四個靶點,由英矽智能的人工智能平台和研發團隊進行評估和開發,並將候選藥物推進到臨床前階段。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account